Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
US8741835B2 · kind B2 · utility
2Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 2, 2011 |
| Grant date | Jun 3, 2014 |
| Priority date | — |
| Expiry date | Feb 13, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 (SEQ ID NO:73) or other suitable ghrelin agonist, to counteract the catabolic effects of dexamethasone and other natural glucocorticoids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.